Chung-Pa-Juhn(Chung-Pa-Juhn) - 药物靶点：MMPs_在研适应症：骨关节炎_专利_临床

概要

基本信息

药物类型

中药

别名

GCSB、Shinbaro

+ [1]

靶点

MMPs

作用机制

MMPs抑制剂(基质金属蛋白酶家族抑制剂)

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

骨关节炎

非在研适应症-

原研机构

Green Cross Holdings Corp.

在研机构

Green Cross Holdings Corp.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2014-04-23),

骨关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

3

项与 Chung-Pa-Juhn 相关的临床试验

NCT01910116 / Completed临床2/3期IIT

Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.

GCSB-5 ("Shinbaro capsule"), is a mixture of 6 oriental herbs that have anti-inflammatory and analgesic effects along with an excellent safety profile. This study is aimed at investigating efficacy of Shinbaro in the treatment of hand osteoarthritis which needs a long term treatment in a placebo controlled, double-blind randomized trial.

开始日期2013-09-01

申办/合作机构

Seoul National University Hospital

[+1]

NCT01604239 / Completed临床4期

A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis

This study investigates if Shinbaro capsule has a lower incident of gastrointestinal events than celecoxib in subjects with osteoarthritis.

开始日期2012-05-01

申办/合作机构

Green Cross Co., Ltd.

NCT01535417 / Completed临床3期

A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee

The purpose of this study is to evaluate the efficacy and safety of 'Shinbaro Capsule', a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee.

开始日期2009-05-01

申办/合作机构

Green Cross Co., Ltd.

100 项与 Chung-Pa-Juhn 相关的临床结果

登录后查看更多信息

100 项与 Chung-Pa-Juhn 相关的转化医学

登录后查看更多信息

100 项与 Chung-Pa-Juhn 相关的专利（医药）

登录后查看更多信息

17

项与 Chung-Pa-Juhn 相关的文献（医药）

2024-02-01·Current Rheumatology Reviews

Efficacy of Herbal Medicine in Hand Osteoarthritis: A Narrative Review

Review

作者: Noorabadi, Parisa ; Aghili, Seyedeh Mehrnaz ; Sahebari, Maryam ; Salari, Masoumeh

Objective:Osteoarthritis (OA) is one of the most prevalent joint disorders in the world that has placed an enormous economic and social burden on governments and healthcare sectors in many countries. Hand OA (HOA) is the most common peripheral arthritis, which is less investigated than knee and hip OA. Due to limited approved drug choices and adverse effects of long-term use of current regimens, we aimed to review the existing evidence that were used as oral herbal medicine to treat HOA.Methods:The PubMed database was searched for both observational and interventional studies that have investigated herbal medicine safety and efficacy in HOA, written in English and published between 2010 and 2022.Results:A total of 5 original articles fulfilled the inclusion criteria, and each article assessed a different herbal regimen. Overall, it seems desirable to add specific herbal treatments to the regimen of HOA patients, specifically in case of early stages of HOA.Conclusion:Currently, the need for a low-risk alternative treatment in HOA patients is felt more than ever. There are reliable references relating to the safety of Korean red ginseng, GCSB-5, XLGB, and GS-GCu in these patients, although their efficacy was limited. Additionally, herbs like curcumin and Boswellia serrata have positively affected patients with knee osteoarthritis. However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients.

2023-12-01·Archives of Rheumatology

GCSB-5 regulates inflammatory arthritis and pain by modulating the mitogen-activated protein kinase signaling pathway in a murine model of rheumatoid arthritis

Article

作者: Young Park, Soo ; Bang, Jihye ; Kim, Sang-Hyon ; Kim, Gyeonghwa ; Kim, Ji-Min ; Jung, Hye Ra

Objectives: This study aimed to determine whether GCSB-5 has anti-inflammatory and antinociceptive effects in mice with collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis (RA), and investigate the influence of GCSB-5 on the mitogen-activated protein kinase (MAPK) pathway.Materials and methods: The experimental animal study was designed to include five groups: CIA mice treated with GCSB-5 (300 mg/kg), GCSB-5 (600 mg/kg), celecoxib (60 mg/kg), or saline for four weeks, and nontreated control mice. The clinical severity of arthritis was scored. Nociceptive thresholds were measured by using a von Frey dynamic plantar analgesimeter. The MAPK pathway was evaluated in mouse synovium. The expression of channels associated with pain signaling was assessed by western blot and immunohistochemical staining.Results: GCSB-5 treatment diminished the severity of clinical arthritis and increased the nociceptive threshold in mice with CIA. Celecoxib, a positive control drug, also showed comparable changes. Clinical arthritis scores were inversely related to mechanical thresholds. GCSB-5 administration decreased the levels of anti-type II collagen antibody and inflammatory cytokines in the sera of mice with CIA. Furthermore, ERK, p38 MAPK, and JNK phosphorylation were downregulated and TRPV1 and ASIC3 expression were decreased in the synovium of GCSB-5-treated mice compared to salinetreated mice. Interleukin-6-induced TRPV1 and ASIC3 upregulation were also inhibited by GCSB-5 in human RA fibroblast-like synoviocytes in vitro.Conclusion: GCSB-5 decreased inflammatory arthritis and pain in a murine model of RA. The results present evidence that GCSB-5 may be beneficial for relieving pain as well as decreasing inflammation in autoimmune arthritis, such as RA.

2023-01-01·Frontiers in neurology

Effects of the administration of Shinbaro 2 in a rat lumbar disk herniation model.

Article

作者: Hong, Jin Young ; Lee, Jinho ; Kim, Won Kyung ; Lee, Sang Kook ; Park, Hyen Joo ; Shin, Joon-Shik ; Koh, Wonil ; Ha, In-Hyuk

The current standard for the pharmacological management of lumbar disk herniation (LDH), involving non-steroidal anti-inflammatory drugs, muscle relaxants, and opioid analgesics, often carries a risk of adverse events. The search for alternative therapeutic options remains a vital objective, given the high prevalence of LDH and the critical impact on the quality of life. Shinbaro 2 is a clinically effective herbal acupuncture against inflammation and various musculoskeletal disorders. Therefore, we explored whether Shinbaro 2 exerts protective effects in an LDH rat model. The results showed that Shinbaro 2 suppressed pro-inflammatory cytokines, interleukin-1 beta, tumor necrosis factor-alpha, disk degeneration-related factors, matrix metalloproteinase-1,-3,-9, and ADAMTS-5 in LDH rats. Shinbaro 2 administration reinstated a behavioral activity to a normal level in the windmill test. The results indicated that Shinbaro 2 administration restored spinal cord morphology and functions in the LDH model. Therefore, Shinbaro 2 exerted a protective effect in LDH via actions on inflammatory responses and disk degeneration, indicating that future research is warranted to assess the action mechanisms further and validate its effects.

100 项与 Chung-Pa-Juhn 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	M09AX	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	韩国	Green Cross Holdings Corp.	2014-04-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01604239 (Pubmed)	临床4期	骨关节炎	761	GCSB-5	糧衊網憲鬱餘獵壓鹽積(餘蓋鏇築艱繭壓構襯製) = 簾築糧壓蓋襯鹽繭壓網築蓋艱壓壓顧衊醖鏇觸 (範選醖繭遞膚窪築艱夢 )	积极	2016-08-02
NCT01910116 (Pubmed \| Med Lett Drugs Ther) 人工标引	临床2/3期	骨关节炎	215	GCSB-5	(網窪願壓觸顧繭鏇襯衊) = 構鏇醖醖築範夢廠繭憲醖鑰選範壓憲襯積壓窪 (壓範遞壓範齋鏇夢壓窪 ) 更多	积极	2016-08-01
				Placebo	(網窪願壓觸顧繭鏇襯衊) = 鑰齋繭襯齋繭窪觸壓襯醖鑰選範壓憲襯積壓窪 (壓範遞壓範齋鏇夢壓窪 ) 更多
NCT01910116 (CTgov)	临床2/3期	骨关节炎	220	Shinbaro (Shinbaro)	遞遞廠壓膚繭淵鹹遞夢(憲鑰夢簾遞醖範膚鹽願) = 積窪遞餘築壓製網鏇繭鹽蓋築齋製選憲鬱簾艱 (鹽壓鹽廠齋觸膚簾鹽鬱, 鑰衊憲築窪壓積鹽鬱構 ~ 鏇衊艱醖築獵壓廠餘選) 更多	-	2015-12-17
				Placebo (Placebo)	遞遞廠壓膚繭淵鹹遞夢(憲鑰夢簾遞醖範膚鹽願) = 襯衊築繭憲淵壓襯鹽廠鹽蓋築齋製選憲鬱簾艱 (鹽壓鹽廠齋觸膚簾鹽鬱, 遞蓋壓鬱醖鑰淵繭構選 ~ 顧築選襯壓夢築廠繭艱) 更多
NCT01910116 (EULAR2015)	临床2/3期	骨关节炎	-	GCSB-5 600 mg	(蓋蓋選膚築構糧艱鹽繭) = 淵積齋餘憲選衊糧繭餘鏇膚積築鑰鑰網願膚觸 (廠簾簾鬱製艱艱觸鑰醖, -23.8 ~ -0.2) 更多	积极	2015-06-10
				Placebo	(蓋蓋選膚築構糧艱鹽繭) = 壓廠鏇窪淵鹹衊遞網簾鏇膚積築鑰鑰網願膚觸 (廠簾簾鬱製艱艱觸鑰醖, -16.7 ~ 6.0) 更多